Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ)

CNY 3.24

(1.25%)

Market Cap (In CNY)

3.33 Billion

Revenue (In CNY)

235.41 Million

Net Income (In CNY)

-75.26 Million

Avg. Volume

51.21 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.72-3.99
PE
-60.2
EPS
-0.05
Beta Value
0.523
ISIN
CNE0000001P8
CUSIP
-
CIK
-
Shares
1029560000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yu Guo
Employee Count
-
Website
https://www.000518shsw.com/shsw
Ipo Date
1993-09-08
Details
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.